Patients with optic disc edema are often brought to the attention of ophthalmologists either as referrals from internists or as a first consultation by a patient with visual symptoms. The ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
About one-third of pheochromocytoma cases are inherited or genetic. Genetic screening can provide critical information about the patient's chance of recovery. Comprehensive screening for family ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
In a series by Petr and Else, mean age at diagnosis in this patient group ... This justifies ruling out pheochromocytoma in NF1 patients before elective surgeries under general anesthetic, as ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback